GLP-1 Medications for Depression (with Obesity)
Persistent low mood, loss of interest, affecting daily function. Bidirectional relationship with obesity; GLP-1 weight loss improves mood; GLP-1 receptors in brain may have direct antidepressant effects. Depression (with Obesity) affects 17.3 million adults with MDD; obesity doubles depression risk, and GLP-1 medications offer a clinically proven treatment option.
Prevalence
17.3 million adults with MDD; obesity doubles depression risk
Recommended Medications
2
Treatment Type
GLP-1 Agonist
How GLP-1 Medications Help with Depression (with Obesity)
Bidirectional relationship with obesity; GLP-1 weight loss improves mood; GLP-1 receptors in brain may have direct antidepressant effects. For patients with depression (with obesity), GLP-1 medications address the underlying metabolic dysfunction that makes weight management difficult. Clinical trials have consistently shown that GLP-1 treatment produces significant improvements in both weight and condition-specific outcomes.
Recommended GLP-1 Medications for Depression (with Obesity)
Based on clinical evidence, the following GLP-1 medications are recommended for patients with depression (with obesity):
Semaglutide
Wegovy / Ozempic
Tirzepatide
Zepbound / Mounjaro
Detailed Medication Guides for Depression (with Obesity)
Depression (with Obesity) & GLP-1 FAQ
Can GLP-1 medications help with depression (with obesity)?
Yes. Bidirectional relationship with obesity; GLP-1 weight loss improves mood; GLP-1 receptors in brain may have direct antidepressant effects. Clinical evidence supports the use of GLP-1 medications like semaglutide and tirzepatide for patients with depression (with obesity).
Which GLP-1 medication is best for depression (with obesity)?
Semaglutide is often the first-line recommendation for depression (with obesity) due to its strong clinical evidence. Your provider will evaluate your specific situation to determine the best option.
How much weight can I lose with GLP-1 if I have depression (with obesity)?
Weight loss results are generally comparable to clinical trial averages (15-22% of body weight), though individual results vary based on the severity of depression (with obesity) and other health factors.
How prevalent is depression (with obesity)?
Depression (with Obesity) affects 17.3 million adults with MDD; obesity doubles depression risk. GLP-1 medications represent a significant treatment advancement for patients dealing with this condition alongside excess weight.